October 25, 2023

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

Gender diversity, equity, and inclusion (DEI) in medicine has long been acknowledged as more than “the right thing to do,” with clear evidence of benefits in innovation, collaboration, and workplace ...

The ASCO Post

May 04, 2025

Patient and Advanced Practitioner Perspectives on Symptom Burden and Symptom Management in Indolent Systemic Mastocytosis

Explore the healthcare journey of ISM patients, revealing the critical need for effective symptom management and patient-centered communication. Source: Kurtin et al., 2025.

JADPRO

April 27, 2023

Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine

Oncology drug development historically has followed a path of sequential phase I, II, and III clinical trials using traditional trial designs, with the goal of achieving regulatory approval. These stu...

JADPRO

March 17, 2025

Survivorship and Advance Care Planning in Cancer

Significant gaps in cancer survivorship care demand urgent attention, especially as new strategies emerge to enhance patient outcomes, says McLendon et al.

JADPRO

November 08, 2023

Advanced Practitioners as Agents of Change: Leveraging Quality Improvement to Improve Practice

Advanced practitioners are essential drivers of quality improvement in hematology and oncology, optimizing workflows and enhancing patient care through structured initiatives.

JADPRO

January 31, 2024

Generic Drug Shortages and Essential Cancer Medicines

Decisions regarding the rationing of chemotherapy are commonplace in many countries around the world—including those where patients must pay for chemotherapy out of pocket—and increasingly so in cance...

The ASCO Post

January 25, 2023

Expert Point of View: Jason Aboudi Mouabbi, MD

A medical oncologist at MD Anderson Cancer Center, Dr. Jason Aboudi Mouabbi, discusses the promising outcomes of the TRIO-US B-12 TALENT trial and the potential of antibody-drug conjugates in treating HER2-low, hormone receptor–positive breast cancer patients.

The ASCO Post

July 02, 2025

Care Optimization for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Receiving Tagraxofusp

Explore the revolutionary impact of tagraxofusp on the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive malignancy.

JADPRO

February 26, 2025

Which Patients Seek Second Opinions?

A Keck Medicine of USC hematologist-oncologist shares his insights on second opinions.

Keck Medicine of USC